MED7

Across TCGA pan-cancer cohorts, MED7 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MED7 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MED7 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED7 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where MED7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.453	0.829	.002	33	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.708	.030	11	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.538	.002	10	view →
PDAC	OS	Median	All	0.365	0.606	.007	10	view →
OV	DFS	Quartile	All	0.653	0.950	.033	8	view →
CCRCC	DFS	Tertile	All	0.775	0.956	.017	6	view →
GBM	DFS	Quartile	All	0.898	0.606	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MED7–HNSC (DFS)

Open the HNSC breakdown →